Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2009-11-04

FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC. Isentress is an antiretroviral therapy used to treat H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Isentress (Raltegravir)

Snippet

SUPPL AP for ISENTRESS (RALTEGRAVIR)